Research Projects & Grants

College/University

  • POEM: A PrOspective Registry of Pediatric Cellular Therapy Patients at risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS), Role: PI, Duke University, (12/2023 - 12/2024) Status: Approved

Federal

  • TSLP and pediatric leukemia mechanisms and treatment, Role: PI, National Cancer Institute/NIH/DHHS, (07/2023 - 07/2024) Status: Approved

For Profit Organization

  • ATARA Biotherapeutics, Inc. ATA129-EBV-302: Multicenter, Open Label, Phase 3 study of Tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-associated post-transplant lymphoproliferative disease after failure of Rituximab or Rituximab and Chemotherapy (ALLELE study), Role: Investigator, Atara Biotherapeutics, Inc., (01/2024 - 01/2025) Status: Approved

Non-Profit Organization

  • The National Marrow donor Program (NMDP) and Center for International Blood and Marrow Transplant Research (CIBMTR) - Contribution of a Blood Sample to the National Marrow Donor Program's Research Sample Repository, Role: PI, National Marrow Donor Program, (10/2023 - 10/2024) Status: Approved
  • NMDP and CIBMTR - Protocol for Research Database for Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries., Role: PI, National Marrow Donor Program, (07/2023 - 07/2024) Status: Approved
  • PTCTC ONC1701 (End RAD): A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based on conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative, Role: PI, Pediatric Blood and Marrow Transplant Consortium, (07/2023 - 07/2024) Status: Approved
  • National Marrow Donor Program® (NMDP) - 10-CBA: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications, Role: PI, National Marrow Donor Program, (09/2023 - 09/2024) Status: Approved